Ciba Vision sales up 4% in first half:
This article was originally published in Clinica
Executive Summary
Ciba Vision benefited from strong demand for high volume lenses in optics as well as a vigorous advance in ophthalmic pharmaceutical sales. The ophthalmic division of Swiss pharmaceutical company Ciba saw sales increase 4% to SwFr 551 million ($467 million) in the first half of 1995 while Ciba's total healthcare sales fell 9% to SwFr 3,873 million. The decline was largely due to the transfer of Ciba's diagnostics business to US-based Chiron.
You may also be interested in...
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.
Philips Portfolio Includes ‘No Single Product That Does Not Use A Type Of AI,’ Says CEO And AI Thought Leader Roy Jakobs
Philips CEO Roy Jakobs talks to Medtech Insight about the medtech firm’s decade-long history of embedding AI into its products and what he expects from the newly released draft framework by the National Academy of Medicine, which he helped develop as co-chair of the Steering Committee.
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.